

1. General Information

Cohort ID	5006_21
Title (Study Name)	COVAC-DM Study
Principal investigator	Prof. Harald Sourij
Contact information	pm-biobank@medunigraz.at
Funding agency	FWF decision pending

2. Description

It is unknown, if people with established diabetes mellitus type 1 or type 2 display a reduced humoral immune response following COVID-19 vaccination as compared to people without this condition. In this study, we prospectively investigate antibody response in people with diabetes, following the first and second dose of vaccination (predominantly mRNA vaccine) as well as 12 months thereafter.

3. Details

ICD 10/O codes / Healthy	E10, E11	
Key words	diabetes mellitus type 1, diabetes mellitus type 2, COVID-19, COVID-19 vaccine	
Collection / Cohort size 11/2021	5967 aliquots from 149 patients	
Informed Consent (IC)	<input checked="" type="checkbox"/> Broad Biobank IC	
	<input checked="" type="checkbox"/> Specific Study IC	
Status	<input checked="" type="checkbox"/> In progress / compl. date: 07/2022	
	<input type="checkbox"/> Completed	
Inclusion criteria	Age distribution	18+
	Sex distribution (f:m)	40:60
	Others	----
Earliest access	As of now	
Quality-standards	<input checked="" type="checkbox"/> ISO 9001:2015 (SOPs)	
Associated publications / references	<p><u>Humoral immune response to COVID-19 vaccination in diabetes is age-dependent but independent of type of diabetes and glycaemic control: The prospective COVAC-DM cohort study</u> Sourij C, Tripolt NJ, Aziz F, Aberer F, Forstner P, Obermayer AM, Kojzar H, Kleinhapfl B, Pferschy PN, Mader JK, Cvirn G, Goswami N, Wachsmuth N, Eckstein ML, Müller A, Abbas F, Lenz J, Steinberger M, Knoll L, Krause R, Stradner M, Schlenke P, Sareban N, Prietl B, Kaser S, Moser O, Steinmetz I, Sourij H; COVAC-DM study group. https://pubmed.ncbi.nlm.nih.gov/34984802/</p> <p><u>Impact of COVID-19 Vaccination on Glycemia in Individuals With Type 1 and Type 2 Diabetes: Substudy of the COVAC-DM Study.</u> Aberer F, Moser O, Aziz F, Sourij C, Ziko H, Lenz J, Abbas F, Obermayer AM, Kojzar H, Pferschy PN, Müller A, Unteregger C, Leitner M, Banfic T, Eckstein ML, Wachsmuth N, Kaser S, Mader JK, Tripolt NJ, Sourij H. https://pubmed.ncbi.nlm.nih.gov/34848490/</p>	

4. Material available (aliquot size) and storage conditions

Material	<input checked="" type="checkbox"/> Serum (580 µl)	<input checked="" type="checkbox"/> -80°C
	<input checked="" type="checkbox"/> EDTA plasma (580 µl)	<input checked="" type="checkbox"/> -80°C
	<input checked="" type="checkbox"/> Na-Citrate plasma (235 µl)	<input checked="" type="checkbox"/> -80°C
	<input checked="" type="checkbox"/> Saliva	<input checked="" type="checkbox"/> -80°C

Dokument erstellt (tt/mm/yyyy):
16/06/2021

Letzte inhaltliche Aktualisierung (tt/mm/yyyy):
17/02/2022